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ABSTRACT Even the finest state-of-the art preclinical drug
testing, usually in primary hepatocytes, remains an imperfect
science. Drugs continue to be withdrawn from the market due
to unforeseen toxicity, side effects, and drug interactions. The
space programmay be able to provide a lifeline. Best known for
rockets, space shuttles, astronauts and engineering, the space
program has also delivered some serious medical science.
Optimized suspension culture in NASA’s specialized suspen-
sion culture devices, known as rotating wall vessels, uniquely
maintains Phase I and Phase II drug metabolizing pathways
in hepatocytes for weeks in cell culture. Previously prohibitively
expensive, new materials and 3D printing techniques have the
potential to make the NASA rotating wall vessel available inex-
pensively on an industrial scale. Here we address the tradeoffs
inherent in the rotating wall vessel, limitations of alternative
approaches for drug metabolism studies, and the market to be
addressed. Better pre-clinical drug testing has the potential to
significantly reduce the morbidity and mortality of one of the
most common problems in modern medicine: adverse events
related to pharmaceuticals.
KEY WORDS drug metabolism . hepatocyte . space .
suspension culture
THE PROBLEMWITH PRE-CLINICAL DRUG
TESTING
To develop and market a new drug, companies must prove
both efficacy and safety. It is clearly more cost effective to
identify and disqualify toxic alternatives as early in the devel-
opment process as possible. In vitro models for ADME/Tox
(absorption, distribution, metabolism and excretion & toxicol-
ogy) screening have been the holy grail of drug development
(1). Not only are in vitro systems more cost effective than in vivo
testing, but they support the guidelines of the National
Research Council and the EPA calling for refinement, reduc-
tion and replacement to minimize the use of in vivo testing in
animals (2).
The liver is the major site of drug metabolism and degra-
dation in vivo. 5–10% of adverse drug reactions are the result
of liver toxicity and a third of all post-market drug withdrawals
are because of liver toxicity (3). The central role of the liver has
led to the use of liver cells (hepatocytes) as a major choice for
in vitro testing systems (1,4). The FDA has already found drug
testing with hepatocyte cell culture to be an acceptable pre-
clinical tool (5).
Despite extensive screening, a surprising number of drug
failures are still not recognized until late stage clinical trials,
after there has been significant investment in the development
of the drug candidate (6–9). A recent study found that about
19% of the drugs that failed in Phase II clinical trials and 21%
of the drugs that failed in Phase III clinical trials were failures
due to safety issues (6,7). One company estimates that clinical
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failures due to liver toxicity cost them more than $2 billion
over the last decade (10). Thus there is a renewed emphasis on
earlier and more accurate toxicology evaluation as one way to
increase future success and avoid adverse clinical reactions
(11)
An ideal in vitro hepatocyte model would include cells with
prolonged robust biosynthetic capacity (e.g. production of al-
bumin) and normal basal and inducible levels of
biotransforming enzymes. Key hepatic biotransforming en-
zymes include those that metabolize drugs through Phase I
(oxidation, reduction and hydrolysis) and/or Phase II (by con-
jugation of functional groups) processes. An ideal in vitro liver
model would also recapitulate the organoid structure of the
intact organ in vivo where hepatocytes cluster to form channels
called bile canaliculi into which they secrete their products.
Current in vitro livermodels fall short of these ideals inmany
ways. Liver slices lose key metabolic enzymes within hours
(2,12). Immortalized hepatocytes remain viable over longer
periods of time, but have lower liver specific enzymes than
primary cells. Furthermore, cell lines only reflect the pheno-
type of a single donor and may miss key variants in the human
population. Induction of stem cells to provide a continuous
supply of hepatocytes is appealing, but efforts to date have
been unable to generate hepatocytes with a stable expression
of relevant enzymes (2). At present, primary human hepato-
cytes represent the Bgold standard^ for preclinical in vitro me-
tabolism and toxicity studies (13). Hepatocytes grown as single
cell suspensions lose polarity, integrity and differentiation
(8,9,14). Primary hepatocytes adherent to plastic dishes are
the most commonly used model but these also begin to de-
differentiation within 24–48 hours.
IS THERE A SPACE-BASED TECHNOLOGY
SOLUTION TO THE CLINICAL DRUG
TOXICITY TESTING PROBLEM?
Three dimensional culture systems are being extensively ex-
plored as a means of extending differentiation and function of
hepatocytes to better reproduce the microenvironment of the
intact liver (14–19). A variety of initiatives have explored the
use of automated, microfluidic, and organ-on-a-chip ap-
proaches (14–20). Hepatocytes grown in gels or on various
bead/fiber scaffoldings display increased and sustained func-
tionality (21–23). However, the inability to adequately oxy-
genate the cells continues to be a major limiting factor (2).
This is where culture techniques, originally designed for space
flight studies, may offer a distinct advantage (14,24–30).
Hepatocytes grown on Earth in NASA’s rotating wall vessel
suspension culture vessels form three-dimensional colonies
that maintain their function for at least several weeks
(14,15,24). These cell colonies closely resemble and function
like natural cells in the human body, which makes them ex-
cellent candidates for preclinical drug testing (14,24–30).
The question to be addressed is whether space flight de-
rived technologies have the potential to predict and prevent
the morbidity, mortality and staggering cost of incidents
where current methods fail to detect toxic pharmaceutical
side effects premarket?What are the pharmacological, tech-
nical and financial tradeoffs inherent is using NASA suspen-
sion culture techniques for preclinical ADME/Tox testing?
This review focuses on the core of preclinical drug testing:
the ability of hepatocytes cultured in the NASA rotating well
vessel, a form of suspension culture optimized to minimize
shear, to maintain Phase I and Phase II drug metabolizing
enzymes, the technology needed, and how this may ad-
dress the problems with current testing, Finally we address
the opportunities to get involved in space-based research.
Through perseverance and development of new technolo-
gy, man walked on the moon, the space shuttle flew, and the
International Space Station was built. The microgravity envi-
ronment of spaceflight has provided an opportunity for new
approaches to pharmacology. For example, microgravity un-
loads muscles and bones, allowing BigPharma to fly rodents in
space and validate new drugs that reverse the effects of muscle
and bone unloading following fracture, rehabilitation, or de-
bility (31). Another opportunity is the facilitation of three di-
mensional organ culture in both real and emulated micro-
gravity (14,15,17). Experiments conducted by NASA’s
Biotechnology Group in the 1980’s on cell behavior in micro-
gravity produced startling results—cells suspended in a
RotatingWall Vessel (RWV) bioreactors formed multicellular
organoids (32–35). This revolutionized cell culture technology
and ultimately led to the production of a life-sustaining RWV-
based artificial liver. NASA suspension culture techniques re-
verse much of the problematic de-differentiation of cells ob-
served during other forms of tissue culture (35–38). The tech-
nology has been applied broadly to diverse cell types including
cancer cells, prostate, kidney, micro-organisms, biofilms, and
plants, to name a few (36,39,40).
NASA AND OPTIMIZATION OF SUSPENSION
CULTURE
Until its reorganization into other programs, NASA’s
Biotechnology Group, based at the Johnson Space Center in
Houston, TX, modeled the problem of optimizing mechani-
cal culture conditions in suspension culture by minimizing
shear and turbulence (33,34,41–46). The rotating wall vessel
is essentially a cylinder of fluid that rotates around its long axis.
Cells cultured in this fluid will tend to settle under the influ-
ence of gravity, but, as the cylinder turns, the cells are lifted
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back into suspension. By adjusting the rotational speed, a
steady state can be achieved where the cells remain in suspen-
sion (Fig. 1a). Fluid flow is near solid body or laminar at most
operating conditions. This avoids the large shear stresses asso-
ciated with turbulent flow and allows introduction of con-
trolled and nearly homogenous shear fields. The culture me-
dium is gently mixed by rotation, avoiding the necessity for
stirring vanes that damage cells by both local turbulence at
their surface and the high flow rates created between the vessel
walls and the vanes. Finally, there is no headspace or air gap
above the medium. This contrasts with roller bottles that are
only partially filled with medium. In roller bottles, air in the
headspace creates turbulence and secondary bubble forma-
tion in the culture medium, which are both potent sources of
extra shear and turbulence.
The reduction of shear and absence of turbulence unique
features of the rotating wall vessel and allow cells to aggregate
into organoids. Shear in a rotating wall vessel depends directly on
the square of the cells’ radius, gravity, and the difference in den-
sity between the cells and the culture medium. Shear is inversely
related to the viscosity of the culture medium (33,35).
Unfortunately density and viscosity of the culture medium are
not independent, so there are limits to how much shear stress on
cells can be reduced in the vessel by matching culture medium
density to the cell density. Hence, by removing the direct effect of
gravity, space affords a cell culturemilieu very close to zero shear.
The original rotating wall vessel, known as the slow turning
lateral vessel (STLV), was shaped like a soup can, and rotated
along its long axis (Fig. 1a and b). The components included
the vessel itself, a coaxial oxygenator, an air pump, a stand
with inbuilt geared rotor, and a tachometer/power supply to
control rotation speed. Average rotation speeds for mamma-
lian cells were about 10 revolutions per minute. The coaxial
oxygenator and the outer wall may rotate at the same slow
(10–16 rpm) rate, avoiding and/or minimizing shear from













Fig. 1 Panel A. A comparison of
the Slow Turning Lateral Vessel
(STLV), High Aspect Ratio Vessel
(HARV) and the Rotating Wall
Perfused Vessel (RWPV). Note that
the co-axial oxygenator in the STLV
is replaced in the HARV by a
breathable membrane as the back
wall of the vessel. The RWPV can
rotate the co-axial oxygenator and
outer wall at different speeds, which
was needed to mix perfusates in
space. Panel B: Schematic of
Rotating Wall Vessel. A 24-V direct
current motor (a) drives a belt that
rotates the cylindrical culture vessel
(b) along its horizontal axis. An air
pump (c) draws incubator air
through a 0.22-micron filter (d) and
discharges it through a rotating
coupling on the shaft that carries the
vessel. The oxygenator (e) is
wrapped around the center post.
Reproduced from Ref 35. Panel C:
Selected rotating wall vessel
volumes and designs. Reproduced
from Ref 35. Panel D. The Rotating
Wall Vessel adapted for use in space
flight. FromNASA technical reports.
http://www.technovelgy.com/
graphics/content/Rotating-Wall-
Bioreactor.jpg. Panel E. Schematic of
a HARV (from www.Synthecon.
com).
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Gas exchange in the STLV was limiting for rapidly grow-
ing cells. Hence a new design was manufactured in a dinner
plate configuration with the entire back becoming a breath-
able membrane. Known as the high aspect rotating vessel
(HARV) (Fig. 1a, c, & e). This design greatly improves gas
exchange but still needs an air pump, a stand with inbuilt
geared rotor, and a tachometer/power supply to control ro-
tation speed. Both the STLV and HARV have rubber seals
that need to be autoclaved at a different temperature to the
other cell culture components. The STLV and HARV main-
tain, and in some cases recover, tissue specific cell differentia-
tion (20,35), but the multiple components with strict engineer-
ing tolerances are expensive and labor intensive to load, re-
feed, and operate.
When the STLV was adapted for utilization in space, ini-
tial flight experiments posed some unanticipated engineering
challenges. In space not only is gravity dramatically reduced
but convection is reduced as well. The hope was to grow large
cell aggregates and induce vascularization. The space flight
unit continuously fed the cell cultures via a perfusion loop
(Fig. 1d). Studies with colored beads and media showed that
the perfused nutrients flowed along the walls with minimal
admixture with the gas and nutrient depleted media sur-
rounding the cells. Rotating the vessel induces minimal
mixing. The problem was solved by differential rotation of
the central coaxial oxygenator and the outer vessel wall.
Differential rotation on the ground reintroduces shear (35),
but also greatly increases vessel complexity and cost.
The next big challenge was bubbles. Both the STLV and
HARV have no headspace free of media, as even a single
bubble disrupts laminar flow, and the resulting turbulence
damages almost all mammalian cells. The current generation
of spaceships purposely have quite low humidity to minimize
the dramatic condensation caused by differential heating of
the vehicle sides by sun exposure and shadow. In the low
humidity, all attempts to seal the STLV flight hardware failed
to prevent bubble formation, as water evaporated through
perfusion lines and wall materials. The engineering answer
to bubble formation was to make the front face of the
HARV slightly domed. Bubbles migrated to the peak of the
dome and were easily removed intermittently. However, this
again induced turbulent rather than laminar flow.
Engineering again solved this problem as a small sculpted
button on the back face of the HARV, rotating at a different
speed to the HARV compensated for the turbulent forces and
reintroduced laminar flow.
THE CASE FOR USING RWV-CULTURED
HEPATOCYTES FOR ADME/TOX TESTING
& The rotating wall vessel has shown significant promise for
improving ADMET test ing with hepatocytes .
Hepatocytes grown on Earth in NASA’s Rotating
Bioreactor form three-dimensional colonies that maintain
their function for at least several weeks (14,15,24). The
most dramatic proof of this approach was the RWV-
based artificial liver that was able to sustain a hepatecto-
mized horse (47) and http://spacesciencesinc.org/pdf/
kelleher_testcases.pdf.
Rat hepatocytes have been cultured initially as spheroids on
culture plates and then transferred into a HARV for further
culturing (14). Morphological evaluation based on electron mi-
croscopy showed that hepatocyte spheroids cultured for 30 days
in the HARV had a compact structure with tight cell-cell junc-
tions, numerous smooth and rough endoplasmic reticulum,
intact mitochondria, and bile canaliculi lined with microvilli.
The viability and differentiated properties of the hepatocytes
cultured in the HARV were further substantiated by the pres-
ence of both phase I oxidation and phase II conjugation drug-
metabolizing enzyme activities, as well as albumin synthesis to a
greater degree than 2-D controls. Homogenates prepared from
freshly isolated hepatocytes and hepatocytes cultured in the
HARV showed similar cytochrome P450 2B activities mea-
sured as pentoxyresorufin-O-dealkylase and testosterone
16-beta-hydroxylase. Further, intact hepatocytes cultured in
the HARV were found to metabolize chlorzoxazone to
6-hydroxychlorzoxazone; dextromethorphan to dextrorphan,
3-methoxymorphinan, and 3-hydroxymorphinan; midazolam
to 1-hydroxymidazolam and 4-hydroxymidazolam; and
7-hydroxycoumarin to its glucuronide and sulfate conjugates
far better than 2D controls (14).
Several others lines of evidence support the contention
that the rotating wall vessel maintains functional hepato-
cytes. Monolayer and spheroid culture of Hep G2 human
liver hepatocellular carcinoma cell line cells demonstrat-
ed distinct global gene expression patterns and functional
phenotype (16). The molecular mechanisms underlying
the enhanced functions of three-dimensional hepatocyte
aggregates including a key role for a diverse array of
hepatocyte-specific functional genes with significant
over-representation of hepatocyte nuclear factor 4α
(Hnf4a) binding sites in their promoters. Other rotating
wall vessel studies confirm that the hepatocytes in the
reconstituted 3D tissue are capable of producing albu-
min and storing glycogen, forming bile canaliculi be-
tween hepatocytes with complicated tubular branches
and express elevated levels of mature hepatocyte genetic
markers compared to hanging droplet and spinner flask
controls (17). But perhaps most importantly, 3D spheroid
cultures of HepG2 cells were far superior to 2D cultures
in terms of how well their data correlated with in vivo
lethal blood plasma levels (18). This suggests that 3D
hepatic spheroids grown in the rotating wall vessel have
excellent potential to predict hepatic toxicity.
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ADAPTING RWV TECHNOLOGY FOR ADMET
TESTING
Although promising in concept as a model for measuring drug
metabolism by hepatocytes, current RWV hardware is too
expensive and labor intensive to support the high throughput
needs of the pharma industry. Current RWVs require expen-
sive hardware and are labor-intensive to load, maintain, and
harvest. These factors make current widespread utilization of
RWVs cost-prohibitive. Instead, industry has turned to using
human hepatocytes in polystyrene plates for drug metabolism
studies, with cells on the edge of their useful life due to loss of
metabolic enzymes.
However the cost and complexity equation is changing
rapidly. The advent of new manufacturing techniques such
as 3D printing, in combination with new materials, developed
just in the last few years (48–50), have set the stage for a new
revolution in cell culture that can be applied to preclinical
drug testing. Further, much simpler approaches have been
applied to the STLV and HARV cell culture techniques de-
signed to minimize shear on cultured cells. For instance, the
vessels can be placed on a device similar to a large hot dog
roller, removing the need for individual rotators, tachometers,
and power supplies. Costs plummet. To simplify culture pro-
cedures, modern self-sealing ports used in clinical medicine
replace open Luer locks. New materials provide more hydro-
phobic membranes for better gas exchange. Inexpensive
microfabrication and 3D printing replace labor-intensive
use-by-use seal installations and assembly requirements.
OTHER DRUG METABOLISM STUDIES SHOW
PROMISE OF THE ISS
We have flown genetically engineered yeast on three flight
missions and found that microgravity provides a cancer-
relevant context that extends and complements current
models. STS-135 experimental data demonstrated a unique
chemogenomic fingerprint of the oxidation status of yeast cells
in microgravity for drug pathway analysis, characterized by
specific changes in mitochondrial and ribosomal respiratory
function with minimal stress response. Microgravity reduces
convection and allows reproduction of redox states and gas
levels in yeast cells that mimic the microenvironment of tu-
mors (51). Altered redox potential with changes in reactive
oxygen species is difficult to model in ground-based cultures
because gravity-dependent convection delivers oxygen and
purges carbon dioxide from the yeast cells in both solid and
liquid culture. Thus microgravity allows yeast-basedmodeling
of drug pathways in ways that are not currently achievable by
any other means in ground-based studies. The baker’s yeast
Saccharomyces cerevisiae has 70% homology with the human ge-
nome, and a data bank of >3200 responses to drugs, small
molecules, and physiological stresses allows space based data
to be tested for unique phenotypic findings (52).
OPPORTUNITIES AND BARRIERS
The International Space Station is improving the portfolio of
available instrumentation on board over time. You can cul-
ture cells in incubators and glove boxes, use centrifuge con-
trols, isolate RNA, perform microscopy and utilize many oth-
er technologies (https://en.wikipedia.org/wiki/Scientific_
research_on_the_International_Space_Station). Diverse
flight hardware is available from NASA as well as US
commercial groups such as Bioserve Space Technologies
(http://www.colorado.edu/engineering/BioServe/),
Techshot (Techshot.com), and NanoRacks (Nanoracks.com),
as well as several international partners (http://global.jaxa.jp;
http://m.esa.int/ESA; http://www.energia.ru/english/;
http://www.asc-csa.gc.ca/eng/) The barriers to involvement
include funding, a tolerance for regulatory paperwork, and a
robust scientific plan.
GETTING INVOLVED
Come to the party. One thing you learn reviewing grants is
that there are amazingly creative and insightful scientists in the
community. We invite and encourage you to apply space re-
sources, and improve space-based research. There are many
funding resources available including, but not limited to:
& Working directly with a commercial partner with a specif-
ic problem in partnership with the NASA ISS –
Commercial Space Utilization Office found at http://
www.nasa.gov/mission_pages/station/research/nlab/
index.html, the Center for the Advancement of Science in
Space (CASIS ) a t h t tp ://www. i s s - ca s i s .o rg/
Opportunities/Solicitations.aspx, or the NASA Small
Business Innovation Research (SBIR/ Small Business
Technology Transfer programs (STTR) found at http://
sbir.nasa.gov/solicitations.
& NASA has multiple branches supporting biomedical re-
search all of which are announced in the NASA
Solicitation and Proposal Integrated Review and
Proposal Evaluation System (NSPIRES), which can be
found at https://nspires.nasaprs.com/external/.
& The Canadian Space Agency has a variety of announce-
ments of opportunities to be found at http://www.asc-csa.
gc.ca/eng/ao/.
& The National Institutes of Health (NIH) and NASA have
sponsored joint research initiatives such as http://www.
niams.nih.gov/News_and_Events/NIH_NASA_
Activities/
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& The Japan Aerospace Exploration Agency (JAXA) an-
nounces opportunities at multiple sites such as http://
www.isas.jaxa.jp/e/enterp/sbms/index.shtml
& The European Space Agency (ESA) provides research op-





Cells respond to perturbations. The question is not whether
cells change in space, but rather what is unique about the
space-based environment, and how can that knowledge be
utilized in ground-based applications? Ground-based controls
are critical and databases of responses from space-based stud-
ies can be used to put uniqueness and utility into context]. In
the United States there is a Presidential Executive Order to
make all data collected with Federal funding publically avail-
able (https://www.whitehouse.gov/the-press-office/2013/
05/09/executive-order-making-open-and-machine-
readable-new-default-government-). As almost all US space
data includes some element of NASA funding, all data is/
will be publically available on US Government websites, in
addition to what can be retrieved from journal or investigator
websites. We recommend you download, reanalyze, and uti-
lize this data freely.
The International Space Station has a life limited by engi-
neering principles on the materials, and the political and fi-
nancial will of the participants. We should not hesitate in our
drive to investigate if the near zero shear of space-based he-
patic cultures allows better prediction of drug interactions and
toxicity than current models, to improve safety profile of pre-
clinical drug testing, and address the current limitations on
ADME/Tox testing, which can result in massive morbidity
and mortality.
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